文献检索文档翻译深度研究

邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

不再提醒

插件&应用

Zotero 插件浏览器插件 Mac 客户端 Windows 客户端微信小程序

高级版

套餐订阅购买积分包

AI 工具

文献检索文档翻译深度研究

关于我们

关于 Suppr 公司介绍联系我们用户协议隐私条款

关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

粤ICP备2023148730 号-1Suppr @ 2025

Bridging the Racial Disparity Gap in Lipid-Lowering Therapy.

作者信息

Kalra Dinesh K

机构信息

Division of Cardiology Rush University Medical Center Lipid Clinic Chicago IL.

出版信息

J Am Heart Assoc. 2021 Jan 5;10(1):e019533. doi: 10.1161/JAHA.120.019533. Epub 2020 Dec 16.

DOI:10.1161/JAHA.120.019533

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7955462/

Abstract

摘要

相似文献

[1]

Bridging the Racial Disparity Gap in Lipid-Lowering Therapy.

J Am Heart Assoc. 2021-1-5

[2]

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.

Clin Ther. 2017-10-14

[3]

Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment.

Eur Heart J. 2019-9-1

[4]

AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.

Circulation. 2013-7-24

[5]

A phase 1 study to evaluate the safety and LDL cholesterol-lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9.

Clin Cardiol. 2017-7

[6]

Lipoprotein(a) Removal Still a Mystery.

J Am Heart Assoc. 2019-2-19

[7]

Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.

J Am Heart Assoc. 2016-6-10

[8]

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.

Nutr Metab Cardiovasc Dis. 2016-10

[9]

Clinical guidance on the contemporary use of proprotein convertase subtilisin/kexin type 9 monoclonal antibodies.

Diabetes Obes Metab. 2019-4

[10]

Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Plasma Ceramide Levels.

Am J Cardiol. 2020-5-15

引用本文的文献

[1]

Striving Towards Equity in Cardiovascular Genomics Research.

Curr Atheroscler Rep. 2025-2-18

[2]

Impact of Guideline-Directed Statin Prescriptions on Cardiovascular Outcomes by Race in a Real-World Primary Prevention Cohort.

JACC Adv. 2024-9-10

[3]

"I don't think people should die young": perspectives of parents with children diagnosed with familial hypercholesterolemia.

J Community Genet. 2024-10

[4]

The Hurdle of Access to Emerging Therapies and Potential Solutions in the Management of Dyslipidemias.

J Clin Med. 2024-7-16

[5]

Estimating the Prevalence of Hypercholesterolemia in Indigenous Populations: A Systematic Review and Meta-Analysis.

JACC Adv. 2023-5-26

[6]

Unique features of dyslipidemia in women across a lifetime and a tailored approach to management.

Am J Prev Cardiol. 2024-4-5

[7]

An Appraisal of the Preventive Effect of Statins on the Development of Graves' Ophthalmopathy: A Hospital-Based Cohort Study.

Ophthalmol Ther. 2024-6

[8]

Racial Disparity in Anthracycline-induced Cardiotoxicity in Breast Cancer Patients.

Biomedicines. 2023-8-17

[9]

Tafolecimab, A Novel Member of PCSK9 Monoclonal Antibodies, Is Worth Expecting in a Chinese Population.

JACC Asia. 2023-7-11

[10]

The evolving landscape of PCSK9 inhibition in cancer.

Eur J Pharmacol. 2023-6-15

本文引用的文献

[1]

Effects of Evolocumab on Low-Density Lipoprotein Cholesterol, Non-High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta-Analysis of Individual Participant Data From Double-Blind and Open-Label Extension Studies.

J Am Heart Assoc. 2021-1-5

[2]

Is race or ethnicity associated with under-utilization of statins among women in the United States: The study of women's health across the nation.

Clin Cardiol. 2020-12

[3]

PCSK9 in African Americans and Caucasians in Relation to Lp(a) Level, Apo(a) Size and Heritability.

J Endocr Soc. 2020-6-11

[4]

Ten-Year Trends in Enrollment of Women and Minorities in Pivotal Trials Supporting Recent US Food and Drug Administration Approval of Novel Cardiometabolic Drugs.

J Am Heart Assoc. 2020-6-2

[5]

Heterogeneity of Treatment and Outcomes Among Asians With Coronary Artery Disease in the United States.

J Am Heart Assoc. 2020-5-18

[6]

JCL roundtable: South Asian atherosclerotic risk.

J Clin Lipidol. 2020

[7]

Low-density lipoprotein cholesterol goals in the secondary prevention of cardiovascular diseases in the Indian population-Is 30 the new 70?

J Clin Lipidol. 2020

[8]

Effects of Race on Statin Prescribing for Primary Prevention With High Atherosclerotic Cardiovascular Disease Risk in a Large Healthcare System.

J Am Heart Assoc. 2019-11-11

[9]

Alirocumab efficacy and safety by race and ethnicity: Analysis from 3 ODYSSEY phase 3 trials.

J Clin Lipidol. 2019-6-27

[10]

Lack of ethnic differences in the pharmacokinetics and pharmacodynamics of evolocumab between Caucasian and Asian populations.

Br J Clin Pharmacol. 2018-10-17

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

推荐工具

医学文档翻译智能文献检索